Specify a stock or a cryptocurrency in the search bar to get a summary
Chromocell Therapeutics Corporation
CHROChromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Address: 4400 Route 9 South, Freehold, NJ, United States, 07728
Analytics
WallStreet Target Price
8.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CHRO
Dividend Analytics CHRO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CHRO
Stock Valuation CHRO
Financials CHRO
Results | 2019 | Dynamics |